Ligand Pharmaceuticals (LGND) Asset Writedowns and Impairment (2010 - 2025)
Ligand Pharmaceuticals (LGND) reported Asset Writedowns and Impairment of $6.2 million for Q4 2025, up 51.92% on a YoY basis from $4.1 million in Q4 2024, and up 51.92% sequentially from $4.1 million in Q4 2024.
Ligand Pharmaceuticals (LGND) Asset Writedowns and Impairment (2010 - 2025) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 9 years of Asset Writedowns and Impairment data on file, last reported at $6.2 million in Q4 2025.
- For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 51.92% year-over-year to $6.2 million; the trailing twelve-month figure through Dec 2025 stood at $10.3 million (up 105.41% YoY), and the FY2025 full-year result was $6.2 million, down 79.72% from the prior year.
- Asset Writedowns and Impairment grew to $6.2 million in Q4 2025, from $4.1 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $6.2 million in Q4 2025 to a low of $924000.0 in Q3 2023.
- A 3-year average of $3.7 million and a median of $4.1 million in 2024 frame the typical range for Asset Writedowns and Impairment.
- Peak annual rise in Asset Writedowns and Impairment reached 51.92% in 2025, while the deepest fall reached 51.92% in 2025.
- Tracing LGND's Asset Writedowns and Impairment over 3 years: stood at $924000.0 in 2023, then soared by 341.67% to $4.1 million in 2024, then jumped by 51.92% to $6.2 million in 2025.
- Business Quant data shows LGND's Asset Writedowns and Impairment at $6.2 million in Q4 2025, $4.1 million in Q4 2024, and $924000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Ligand Pharmaceuticals | 5.92 Bn | 5.14 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.20 Mn |
| Dec 31, 2025 | 6.20 Mn |
| Dec 31, 2024 | 4.08 Mn |
| Dec 31, 2024 | 4.08 Mn |
| Sep 30, 2023 | 924,000.00 |
| Sep 30, 2023 | 924,000.00 |
| Mar 31, 2015 | 2.40 Mn |
| Mar 31, 2015 | 2.40 Mn |
| Dec 31, 2014 | 3.25 Mn |
| Dec 31, 2014 | 3.25 Mn |
| Sep 30, 2014 | 16,000.00 |
| Sep 30, 2014 | 16,000.00 |
| Jun 30, 2014 | -16,000.00 |
| Jun 30, 2014 | -16,000.00 |
| Dec 31, 2013 | 341,000.00 |
| Dec 31, 2013 | 341,000.00 |
| Jun 30, 2013 | 500,000.00 |
| Jun 30, 2013 | 500,000.00 |
| Mar 31, 2013 | 1.24 Mn |
| Mar 31, 2013 | 1.24 Mn |